Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Viral arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Viral arthritis. Displaying page 1 of 1.
    EudraCT Number: 2006-006373-25 Sponsor Protocol Number: A3921029 Start Date*: 2007-03-23
    Sponsor Name:Pfizer, S.A.
    Full Title: ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO Y EL ESTADO FUNCIONAL DE SUJETOS CON ARTRITIS REUMATOIDE INCLUIDOS PREVIAMENTE EN ESTUDIOS DE CP-690,550 A PROSPECTIVE OBS...
    Medical condition: CP-690,550 se está desarrollando como fármaco antirreumático modificador de la enfermedad (FARME) para el tratamiento de la artritis reumatoide (AR). CP 690,550 is being developed as a disease mo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) SE (Completed) SK (Completed) CZ (Completed) GR (Completed) DE (Completed) FI (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003280-40 Sponsor Protocol Number: A720B20 Start Date*: 2009-06-30
    Sponsor Name:Public Health Service Amsterdam
    Full Title: Response to hepatitis A and B vaccine among children with immunesuppression due to either hiv or immunesuppressive medication
    Medical condition: The effectiveness of Ambirix will be investigated in 2 groups: 1) children with hiv-infection, with CD4 counts > 15% 2) children with a rheumatic disease for which immune-suppressive medication is ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002725 Anti-HIV positive LLT
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006007-15 Sponsor Protocol Number: JAKAR Start Date*: 2022-09-01
    Sponsor Name:Leiden University Medical Center (LUMC)
    Full Title: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis
    Medical condition: patients with ACPA-positieve active RA
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000570-35 Sponsor Protocol Number: 01-2015 Start Date*: 2016-02-10
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration.
    Medical condition: Occult Hepatitis B virus Infection (OBI) in patients with rheumatologic diseases candidate to treatment a finite duration (less than 18 months) with potent immune suppressive drugs
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037163 Psoriatic arthropathies HLT
    20.1 100000004862 10057212 Hepatitis viral infections HLT
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002958-21 Sponsor Protocol Number: HCV-art Start Date*: 2017-05-16
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: Study HCV-art: An Open-Label, pilot Study, to Explore the Clinical Safety and Efficacy of Sofosbuvir/Ledipasvir in Hepatitis C Virus (HCV) Chronic Patients with Arthritis
    Medical condition: Chronic HCV associated with chronic arthritis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10066550 Chronic arthritis LLT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002396-33 Sponsor Protocol Number: WA17044 Start Date*: 2005-12-27
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Estudio internacional, randomizado, doble ciego, para evaluar la eficacia y seguridad de diversos regímenes de retratamiento con rituximab en combinación con metotrexato, en pacientes con AR que ma...
    Medical condition: Artritis Reumatoide (Rheumatoid arthritis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) FI (Completed) IT (Completed) GB (Completed) SK (Completed) HU (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2016-002134-74 Sponsor Protocol Number: FLU-v004 Start Date*: 2016-07-27
    Sponsor Name:PepTcell Limited (trade name SEEK)
    Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model
    Medical condition: Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001290-23 Sponsor Protocol Number: C4591024 Start Date*: Information not available in EudraCT
    Sponsor Name:BioNTech SE
    Full Title: A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE
    Medical condition: Protection against COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003605-15 Sponsor Protocol Number: IgPro20_3001 Start Date*: 2015-02-26
    Sponsor Name:CSL Behring AG
    Full Title: A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)
    Medical condition: Primary Immune Deficiency (PID)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-000541-41 Sponsor Protocol Number: N/A Start Date*: 2021-04-22
    Sponsor Name:Oslo University Hospital
    Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial
    Medical condition: SARS-CoV-2- infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001430-34 Sponsor Protocol Number: 10-TT-EP-003 Start Date*: 2012-08-14
    Sponsor Name:Deutsche Homöopathie-Union, DHU-Arzneimittel GmbH & Co. KG
    Full Title: Therapeutic effectiveness, safety and tolerability of Tonsilotren tablets in patients (6 to 60 years old) with chronic tonsillitis. A randomized, international, multicenter, controlled clinical t...
    Medical condition: Chronic tonsillitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10009152 Chronic tonsillitis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001836-44 Sponsor Protocol Number: UCL/11/0119 Start Date*: 2012-06-11
    Sponsor Name:University College London
    Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
    Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020002-15 Sponsor Protocol Number: A3921061 Start Date*: 2010-11-15
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Medical condition: Moderate To Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Completed) NL (Completed) FI (Prematurely Ended) ES (Completed) DK (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) AT (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003877-87 Sponsor Protocol Number: SCGAM-01 Start Date*: 2014-03-12
    Sponsor Name:Octapharma Pharmazeutika Prod.Ges.m.b.H
    Full Title: CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
    Medical condition: Primary immunodeficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004139-21 Sponsor Protocol Number: CTU/2017/306 Start Date*: 2020-04-22
    Sponsor Name:University College London
    Full Title: A randomised prospective open label pilot trial comparing mycophenolate mofetil (MMF) with no immunosuppression in adults with limited cutaneous systemic sclerosis MINIMISE-Pilot (Mycophenolate in ...
    Medical condition: Limited cutaneous systemic sclerosis (lcSSc)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10011380 CREST syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002368-18 Sponsor Protocol Number: HEPB-VAC-01 Start Date*: 2018-07-25
    Sponsor Name:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
    Full Title: Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with inc...
    Medical condition: 1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab. 2. breast and lung cancer undertreated by chemotherapy 3. HIV 4. Haematopoietic progenitor cell transplantation (TCPH).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058467 Lung neoplasm malignant PT
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    20.0 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004718-32 Sponsor Protocol Number: NL72607.041.20 Start Date*: 2020-10-09
    Sponsor Name:UMC Utrecht
    Full Title: Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized co...
    Medical condition: Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006745-13 Sponsor Protocol Number: ZLB06_001CR Start Date*: 2007-07-11
    Sponsor Name:CSL Behring AG
    Full Title: A Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency
    Medical condition: PID (Primary Immunodeficiency)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064859 Primary immunodeficiency syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) ES (Completed) SE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:10:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA